About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Application of the New Continuation Rules to Divisional Applications | Main | The "Word" on the New Continuation Rules (from the USPTO Webcast) - Part II »

August 23, 2007

Comments

At this point, it seems likely that:

1) I will not file applications with more than 25 claims

2)I willfile many, smaller applications, being sure that the subject matter in one application is not disclosed in other, related applications, e.g., the A-ring is aryl in one application, the A-ring is heteroaryl in another, etc. (I do a lot of pharmaceutical work, not sure how the EE, ME, CS people will handle this)

3) appeals will become more common

4) patent prosecution related expenses will go up

5) claims of inequitable conduct will go up - if anyone actually characterizes a reference

6) confusion will reign for a long time

7) shoddy office actions will no longer be tolerated

8) the pre-appeal process will be utilized more often

9) paralegals will spend a lot more time making sure IDS's are filed as soon as possible

and

10) more lawsuits challenging the rules are coming.

Dear Interested:

I agree. As to your point #7, we are preparing a primer on patent examining procedure (more concise than the MPEP) to identify the types of actions that are objectively "shoddy."

Thanks for the comment.

The comments to this entry are closed.

September 2022

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30